EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Targeting the extracellular matrix with Tenascin-C-specific CAR T cells extends survival in preclinical models of glioblastoma

Jana de Sostoa, Eliana Marinari, Martin Pedard, Valérie Widmer, Suzel Davanture, Karl Schaller, Stephanie Tissot, Michele De Palma, Benita Wolf, Gertraud Orend, Valérie Dutoit, Denis Migliorini

Journal for ImmunoTherapy of Cancer · 2025-11 · 13 (11) · e011382

DOI: 10.1136/jitc-2024-011382 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 04.11.2025. Verfasst von Jana de Sostoa und 11 weiteren Autor:innen. Beteiligte Einrichtung: Brain Tumor and Immune Cell Engineering Laboratory, Faculty of Medicine, University of Geneva, Geneva, Switzerland. Hauptthemen laut MEDLINE: Glioblastoma, Tenascin, Immunotherapy, Adoptive, Extracellular Matrix. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Association Frédéric Fellay, Ligue Genevoise Contre le Cancer, Fondation privée des Hôpitaux universitaires de Genève.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Glioblastoma (GBM) is an aggressive brain tumor associated with poor outcome and limited treatment options. Chimeric antigen receptor (CAR) T cells targeting cell surface antigens were shown to induce tumor regression in patients with GBM, although efficacy was transient. To broaden the range of tumor-restricted antigens, we developed CAR T cells targeting Tenascin-C (TNC), a secreted extracellular matrix protein that is overexpressed in GBM and plays a critical role in tumor progression.

Methods

Second-generation CAR T cells were engineered to target the alternatively spliced fibronectin type III (FNIII)-D domain of TNC using a single-chain variable fragment isolated from the R6N antibody and coupled to a CD28 costimulatory domain. TNC-CAR T cells were evaluated in vitro for antigen specificity, activation, and cell proliferation using TNC-expressing patient-derived GBM cell lines cultured as adherent cells or as neurospheres. Reactivity toward purified TNC protein, tumor supernatant, and ex vivo patient tumor samples was also assessed. Cytotoxic CAR T-cell activity was tested against TNC-positive and TNC-negative GBM cell lines, including bystander effects mediated by secreted TNC. In vivo efficacy and safety were determined in NOD scid gamma mice bearing patient-derived GBM tumors.

Results

TNC-CAR T cells demonstrated activation when exposed to TNC-positive GBM cells, cell-derived supernatants, or purified TNC protein. They exhibited potent cytotoxicity against TNC-expressing, GBM-derived adherent cells and neurospheres, and induced bystander killing of TNC-negative cells in the presence of either TNC-secreting cells or purified TNC. In vivo, TNC-CAR T cells efficiently infiltrated tumors, triggered cancer cell apoptosis, and significantly extended survival of mice bearing patient-derived GBM, with no evidence of off-tumor toxicity. Notably, TNC-CAR T cells were activated exclusively in the presence of tumor samples and showed no reactivity toward patient-derived non-tumor tissues.

Conclusions

Targeting the alternatively spliced FNIII-D domain of TNC with CAR T cells offers a promising therapeutic approach for GBM. TNC-CAR T cells demonstrated specific tumor recognition, robust antitumor activity and the ability to induce bystander effects mediated by secreted TNC. Their efficacy in preclinical models, combined with a favorable safety profile, underscores their potential for clinical translation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaTenascinImmunotherapy, AdoptiveExtracellular MatrixReceptors, Chimeric AntigenBrain NeoplasmsT-LymphocytesHumansAnimalsMiceCell Line, TumorXenograft Model Antitumor AssaysFemaleDisease Models, Animal

Stichwörter der Autor:innen

Chimeric antigen receptor - CARGlioblastomaImmunotherapySolid tumor

Substanzen

TenascinReceptors, Chimeric AntigenTNC protein, human

Autor:innen und Institutionen

  • Brain Tumor and Immune Cell Engineering Laboratory, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
  • Division of Neurosurgery, Department of Clinical Neurosciences, Geneva University Hospitals, Geneva, Switzerland.
  • Centre des Thérapies Expérimentales, Immune Landscape Laboratory, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
  • Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Swiss Federal Institute of Technology Lausanne, Lausanne, Switzerland.
  • Ludwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland.
  • Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland.

Förderung

  • Association Frédéric Fellay
  • Ligue Genevoise Contre le Cancer
  • Fondation privée des Hôpitaux universitaires de Genève
  • Institut National Du Cancer
  • Fonds Lionel Pierrer
  • ISREC Foundation
  • Fondation Anita et Werner Damm-Etienne
  • Swiss National Science Foundation

Zitieren

APA

de Sostoa, J., Marinari, E., Pedard, M., Widmer, V., Davanture, S., Schaller, K., Tissot, S., De Palma, M., Wolf, B., Orend, G., Dutoit, V., & Migliorini, D. (2025). Targeting the extracellular matrix with Tenascin-C-specific CAR T cells extends survival in preclinical models of glioblastoma. Journal for ImmunoTherapy of Cancer, 13(11), e011382. https://doi.org/10.1136/jitc-2024-011382

Vancouver

de Sostoa J, Marinari E, Pedard M, Widmer V, Davanture S, Schaller K, et al. Targeting the extracellular matrix with Tenascin-C-specific CAR T cells extends survival in preclinical models of glioblastoma. Journal for ImmunoTherapy of Cancer. 2025;13(11):e011382. doi:10.1136/jitc-2024-011382

BibTeX
@article{deSostoa2025,
  author = {de Sostoa, Jana and Marinari, Eliana and Pedard, Martin and Widmer, Valérie and Davanture, Suzel and Schaller, Karl and Tissot, Stephanie and De Palma, Michele and Wolf, Benita and Orend, Gertraud and Dutoit, Valérie and Migliorini, Denis},
  title = {Targeting the extracellular matrix with Tenascin-C-specific CAR T cells extends survival in preclinical models of glioblastoma},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2025},
  volume = {13},
  number = {11},
  pages = {e011382},
  doi = {10.1136/jitc-2024-011382}
}
Kostenlos starten →